pyrroles has been researched along with Breast Neoplasms in 250 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.80) | 18.7374 |
| 1990's | 4 (1.60) | 18.2507 |
| 2000's | 49 (19.60) | 29.6817 |
| 2010's | 168 (67.20) | 24.3611 |
| 2020's | 27 (10.80) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, W; Fu, Y; Liu, C; Liu, X; Qian, C; Wang, W; Xu, Y; Yan, Y; Zhu, K | 1 |
| Aukhadieva, A; Bikinieva, F; Boichuk, S; Dunaev, P; Galembikova, A; Gankova, K; Igidov, N; Kopnin, P; Novikova, M; Syuzov, K; Zykova, S | 1 |
| Albert, V; Brockhoff, G; Gaumann, A; Hummel, M; Jagla, W; Lammert, H; Ortmann, O; Piendl, G; Wege, AK; Yousseff, D | 1 |
| Andrikopoulou, A; Chatzinikolaou, S; Dimopoulos, MA; Kaparelou, M; Liontos, M; Panourgias, E; Zagouri, F | 1 |
| Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; de Bruin, EC; Foxley, A; Howell, SJ; Ingarfield, K; Jones, RH; Meissner, M; Moon, S; Morgan, S; Schiavon, G; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Atmaca, H; Ilhan, S; Korkmaz, E; Zora, M | 1 |
| Aydın, EB; Aydın, M; Sezgintürk, MK | 1 |
| Abdel-Aal, FAM; Abdeltawab, AA; Kamel, RM; Mohamed, AI; Mohamed, FA | 1 |
| Amin, T; Bhagat, M; Chhabra, S; Goswami, A; Kapoor, KK; Kotwal, P; Mir, KB; Nandi, U; Parkesh, R; Sharma, RP; Slathia, N; Tsering, D | 1 |
| Akcakanat, A; Chen, H; Damodaran, S; DiPeri, TP; Evans, KW; Ha, MJ; Kirby, BP; Meric-Bernstam, F; Mills, GB; Ng, PKS; Rodon Ahnert, J; Saridogan, T; Scott, S; Yuca, E; Zhao, M; Zheng, X | 1 |
| Chang, TT; Chen, CL; Li, WS; Shih, CY | 1 |
| Ahmed, S; Cheung, KL; Cheung, SYA; Coleman, RE; Cullberg, M; de Bruin, EC; Deb, R; Evans, A; Finlay, P; Foxley, A; Gee, JMW; Holcombe, C; Horgan, K; Jahan, A; Koulai, L; Lindemann, JPO; Littleford, R; Pass, M; Rauchhaus, P; Rea, D; Robertson, JFR; Rugman, P; Schiavon, G; Skene, A | 1 |
| Alchami, F; Bale, C; Bezecny, P; Butler, R; Carucci, M; Casbard, A; Cox, C; Foxley, A; Howell, SJ; Joffe, J; Jones, RH; Madden, TA; Moon, S; Twelves, C; Venkitaraman, R; Waters, S | 1 |
| Danciu, O; Emmadi, R; Hoskins, K; Kumar, S; Nair, RS; Rana, A; Rana, B; Sethupathi, P; Singh, SK; Sinha, SC; Sondarva, G; Thatcher, GRJ; Viswakarma, N | 1 |
| Chen, Q; Fu, H; Gao, J; Okrah, EA; Wang, Q | 1 |
| Laxman, K; Ravikanth, M; Reddy, BPK; Robinson, A; Srivastava, R | 1 |
| Du, YY; Gu, KS; Jiao, Y; Lei, Y; Liu, WT; Wei, W; Zhan, MN; Zhang, CJ; Zhang, TT; Zhang, YY; Zhao, CC | 1 |
| Abraham, J; Baird, RD; Bliss, JM; Braybrooke, JP; Bye, H; Cameron, D; Cutts, R; Gevensleben, H; Hubank, M; Kernaghan, S; Kilburn, LS; Kingston, B; Macpherson, IR; Martin, S; Moretti, L; Oikonomidou, O; Randle, K; Rea, D; Ring, A; Roylance, R; Shaaban, A; Snowdon, C; Stephens, P; Turner, NC; Tuthill, M; Wardley, AM; Wilkinson, K; Winter, MC | 1 |
| Ding, W; Fan, K; Li, Y; Wu, S; Xu, L; Zhang, L; Zhang, R | 1 |
| Alhudaithi, SS; Almuqbil, RM; Bielski, ER; Bos, PD; da Rocha, SRP; Du, W; Sunbul, FS; Zhang, H | 1 |
| Arteaga, CL; Chen, AP; Conley, BA; Doyle, LA; Flaherty, KT; Gray, RJ; Hamilton, SR; Harris, LN; Hong, F; Kalinsky, K; Li, S; McCourt, CK; McShane, LM; Mitchell, EP; O'Dwyer, PJ; Patton, D; Rubinstein, LV; Sachdev, JC; Williams, PM; Zwiebel, JA | 1 |
| He, RR; Kuang, XP; Li, WX; Li, YF; Liu, M; Luo, X; Wu, YP; Yang, X; Zhang, J | 1 |
| Cho, HY; Choi, HG; Jee, JG; Kim, H; Kim, I; Kim, ND; Ko, E; Lee, Y; Seo, KA; Son, JB | 1 |
| Atmaca, H; Ilhan, S; Yilmaz, ES; Zora, M | 1 |
| Alonso-Diez, Á; Alonso-Miguel, D; Clares, I; García-San José, P; Peña, L; Pérez-Alenza, MD; Portero, M; Valdivia, G | 1 |
| Andreidesz, K; Bagone Vantus, V; Bognar, Z; Gallyas, F; Isbera, M; Kalai, T; Koszegi, B; Kovacs, D; Kovacs, K; Szabo, A; Vamos, E | 1 |
| Agalou, A; Argyros, O; Asvos, X; Beis, D; Davos, CH; Fokas, D; Karampelas, T; Papakyriakou, A; Tamvakopoulos, C; Varela, A | 1 |
| Browne, BC; Canonici, A; Crown, J; Ivers, L; Madden, SF; McDermott, MSJ; O'Brien, NA; O'Donovan, N | 1 |
| Choi, HG; Jeong, JH; Kim, JO; Nguyen, HT; Phung, CD; Shin, BS; Thapa, RK; Tran, TH; Yong, CS | 1 |
| Morimoto-Kamata, R; Yui, S | 1 |
| Gaboriau, D; Quachthithu, H; Rainey, MD; Santocanale, C | 1 |
| Agah, M; Clarke, R; Kikkeri, K; Shajahan-Haq, AN; Soltanian-Zadeh, S; Strobl, J | 1 |
| Afif-Rider, S; Bezabeh, B; Breen, S; Chen, C; Dimasi, N; Dixit, R; Gunsior, M; Harper, J; Hinrichs, MJM; Howard, PW; Masterson, L; Patel, N; Rebelatto, M; Reed, M; Ryan, PC; Ryan, PM; Tiberghien, A; Vashisht, K; Yu, XQ; Zheng, B; Zhong, H | 1 |
| Ashrafi, GH; Modjtahedi, H; Seddon, AM; Stanley, A | 1 |
| Al Anazi, FE; Al-Atawi, FO; Alanazi, IO; Alsaad, AM; Alshamsan, A; Belali, OM; Korashy, HM; Maayah, ZH | 1 |
| Darwish, M; Dela Cruz-Chuh, J; Flygare, JA; Gregson, SJ; Gunzner-Toste, J; Howard, PW; Kang, GD; Kozak, KR; Lau, J; Lewis Phillips, GD; Li, G; Masterson, LA; Ohri, R; Pillow, TH; Polson, A; Raab, H; Safina, BS; Spencer, SD; Wei, B; Yu, SF | 1 |
| Bosch, A; Costa, C | 1 |
| Hao, M; Hou, S; Tang, C; Wang, B; Wang, C; Xue, L; Yuan, H; Zhang, C; Zhu, L | 1 |
| Chen, Y; Chen, YH; Ding, J; Gao, YL; Hu, LD; Liu, XL; Ma, QY; Meng, LH; Sun, YM; Tan, C; Wang, BB; Wang, Y; Wang, YX; Xu, YC; Yang, CH; Zhang, YC | 1 |
| Brunton, VG; Byron, A; Derksen, PWB; Gómez-Cuadrado, L; Mandoli, A; Martens, JH; Rätze, M; Renes, J; Singh, AA; Strengman, E; Stunnenberg, HG; Tenhagen, M; Teo, K; van Amersfoort, M; van Diest, PJ | 1 |
| Kaur, M; Singh, P | 1 |
| Chen, Y; Deng, J; Duan, Z; Evers, BM; Ghaffari, S; Guo, W; He, Y; Lin, PC; Lin, Y; Liu, J; Liu, S; Shi, J; Stewart, RL; Tai, F; Wang, C; Wang, Y; Wu, Y; Zeng, L; Zhang, Q; Zhou, BP; Zhou, MM | 1 |
| Baulin, V; Busser, B; Coll, JL; Couvet, M; Gilson, P; Henry, M; Hurbin, A; Josserand, V; Lafanechère, L; Mahuteau-Betzer, F; Orlowska, A; Vanwonterghem, L; Vollaire, J; Werner, M | 1 |
| Aparna, HS; Girish, KS; Harsha Raj, M; Paul, M; Rashmi, KC; Salimath, BP | 1 |
| Alewine, C; Antignani, A; FitzGerald, D; Gadina, M; Hewitt, SM; Simon, N | 1 |
| Bender, S; Boemer, U; Collin, MP; Ellinghaus, P; Grünewald, S; Héroult, M; Hess-Stumpp, H; Ince, S; Kneip, C; Kopitz, C; Lustig, K; Mumberg, D; Politz, O; Thuss, U; Ziegelbauer, K; Zopf, D | 1 |
| Alarcón, E; Armstrong, AC; Cheung, SYA; Corcoran, C; Cullberg, M; Davies, BR; de Bruin, EC; Foxley, A; Gómez Villanueva, A; Lindemann, JPO; López Chuken, YA; Maudsley, R; Moschetta, M; Oliveira, M; Outhwaite, E; Pass, M; Pérez-Fidalgo, JA; Philco, M; Rugman, P; Sablin, MP; Schiavon, G; Tamura, K; Turner, NC | 1 |
| Carr, TH; Citi, V; Cutts, R; de Bruin, EC; Fenwick, K; Garcia-Murillas, I; Hrebien, S; Kozarewa, I; Maudsley, R; McEwen, R; Oliveira, M; Ratnayake, J; Schiavon, G; Turner, N | 1 |
| Amini, M; Hamel, E; Saeedian Moghadam, E; Shahsavari, Z | 1 |
| Feng, T; Li, P; Peng, L; Qin, S; Wan, J; Yuan, P; Zhang, L; Zhao, T | 1 |
| Guo, Z; He, J; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X | 1 |
| Bendahl, PO; Bjarnadottir, O; Borgquist, S; Grabau, D; Jirström, K; Johannesson, H; Loman, N; Romero, Q; Rose, C; Rydén, L; Uhlén, M | 1 |
| Hou, T; Lee, SM; Li, P; Li, S; Li, Y; Pan, P; Shen, M; Yu, H; Zhang, L; Zhou, S | 1 |
| Arias-Romero, LE; Chernoff, J; Hoeflich, KP; Huang, M; Villamar-Cruz, O | 1 |
| Hahn, PJ; Halleran, DR; Hudson, SG; Hutchison, RE; Nevaldine, B; Shapiro, A | 1 |
| Chen, D; Murugesan, S; Nadkarni, DH; Qin, JJ; Velu, SE; Wang, H; Wang, MH; Wang, W; Zhang, R | 1 |
| Guerin, E; Kerbel, RS; Man, S; Xu, P | 1 |
| Chang, TT; Chiao, YP; Jao, SC; Li, WS; Lu, CK; More, SV | 1 |
| Ding, LJ; Jiang, ZF; Meng, XY; Song, ST; Sun, B; Wu, SK; Zhao, X | 1 |
| Arteaga, CL; Davies, BR; Fox, EM; Kuba, MG; Miller, TW | 1 |
| Bachelot, T; Blasinska-Morawiec, M; Capitain, O; Cognetti, F; Crown, JP; Davidson, N; Diéras, V; Fasching, PA; Fountzilas, G; Greil, R; Huang, X; Kern, KA; Kreienberg, R; Liedtke, C; Miller, WH; Paolini, J; Ramos, M; Romieu, G; Staroslawska, E; Tassell, V; Wildiers, H; Yardley, DA | 1 |
| Aoyama, K; Asano, M; Dougan, DR; Hamada, T; Hashimoto, K; Ishikawa, T; Mol, CD; Morishita, N; Saito, B; Shiokawa, Z; Sumi, H; Yabuki, M; Yoshida, S; Yoshimatsu, M | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S | 1 |
| Askeland, RW; Cyr, AR; Gillum, MP; Spanheimer, PM; Weigel, RJ; Woodfield, GW | 1 |
| Bertheau, P; Bousquet, G; de Bazelaire, C; Faivre, S; Ferreira, I; Germain, S; Janin, A; Leboeuf, C; Mongiat-Artus, P; Raymond, E; Varna, M; Wang, L | 1 |
| Ebos, JM; Francia, G; Guerin, E; Kerbel, RS; Lee, CR; Man, S; Xu, P | 1 |
| Al-Mahrouki, A; Czarnota, GJ; El Kaffas, A; Giles, A; Tran, WT | 1 |
| Yaqub, F | 1 |
| Basaran, G; Cabuk, D; Dane, F; Korkmaz, T; Seber, S; Telli, F; Teomete, M; Turhal, S; Yumuk, PF | 1 |
| Bachelot, T; Blay, JY; Cesari, R; Garcia-Saenz, JA; Gutierrez, M; Huang, X; Kern, KA; Khosravan, R; Kozloff, MF; Lluch, A; Pivot, X; Prady, C; Tassell, V; Verma, S; Wang, Z | 1 |
| Balasis, ME; Cheng, C; Li, J; Li, R; Liu, Y; Nicolaou, KC; Pan, L; Qin, Y; Sebti, SM; Simmons, NL; Song, H | 1 |
| Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Park, HS; Ro, J; Song, HS; Yoo, C | 2 |
| Abrantes, AM; Botelho, MF; Brito, AF; Gonçalves, C; Laranjo, M; Oliveira, AS; Pinho e Melo, TM; Santos, K; Sarmento Ribeiro, AB; Soares, MI | 1 |
| Chen, X; Li, Y; Meng, Q; Sun, H; Xu, P; Yin, Q; Yu, H; Zhang, Z | 1 |
| Chen, KF; Chu, PY; Hung, MH; Kao, YP; Liu, CY; Ni, MH; Shiau, CW; Su, JC; Tai, WT; Tseng, LM; Wang, DS | 1 |
| Almendro, V; Bessarabova, M; Caldas, C; Carver, K; Ekram, MB; Feng, J; Kim, JH; Liu, XS; Maruyama, R; Moen Vollan, HK; Nikolsky, Y; Peluffo, G; Polyak, K; Rueda, OM; Russnes, HG; Sun, H; Takagi, S; Vaske, C; Wu, Z; Yamamoto, S; Zhao, X; Zucca, M | 1 |
| Cao, J; Hu, X; Lv, F; Wang, B; Wang, L; Wang, Z; Zhang, J | 1 |
| Hyder, SM; Liang, Y; Mafuvadze, B | 1 |
| Berlot, CH; Childress, C; Lin, Q; Mi, W; Robishaw, J; Shabahang, M; Sudol, M; Yang, W | 1 |
| Alsaid, MS; Arafa, RK; Ceruso, M; Ghorab, MM; Nissan, YM; Supuran, CT | 1 |
| Dewhurst, S; Feng, C; Gelbard, HA; Granger, M; Polesskaya, O; Rhoo, KH; Sur, J | 1 |
| Elledge, R; Foreman, C; Hilsenbeck, SG; Niravath, P; Rimawi, M; Rodriguez, A; Tham, YL; Wang, T | 1 |
| Ji, X; Li, J; Li, L; Lu, W; Ma, Y; Mou, Z; Wang, S; Wu, K; Zhou, T | 1 |
| Aiello, F; Avino, S; Garofalo, A; Grande, F; Maggiolini, M; Rosano, C; Santolla, MF | 1 |
| Bergh, J; Foukakis, T; Giorgetti, C; Hedayati, E; Jacobsson, H; Lindström, LS; Lövrot, J; Sandqvist, P; Xie, H | 1 |
| Carr, JC; De Andrade, JP; Kulak, MV; Lorenzen, AW; Spanheimer, PM; Sugg, SL; Weigel, RJ; Woodfield, GW | 1 |
| Bracken, CP; Crampin, EJ; Cursons, J; Davis, MJ; Foroutan, M; Leuchowius, KJ; Redfern, A; Street, I; Thompson, EW; Tomaskovic-Crook, E; Waltham, M | 1 |
| Khoo, BL; Kumar, P; Lee, SC; Lim, CT; Nandi, S; Ow, SG; Tan, TZ; Thiery, JP; Warkiani, ME | 1 |
| Jeon, M; Kim, S; Lee, J; Lee, JE; Nam, SJ | 1 |
| Crafter, C; Davies, BR; Dudley, P; James, NH; Klinowska, T; Tang, E; Vincent, JP | 1 |
| Campbell, H; Davies, BR; Dowsett, M; Gao, Q; Guest, SK; Johnston, S; Liccardi, G; Marangoni, E; Martin, LA; Pancholi, S; Polanska, UM; Rani, A; Ribas, R; Simigdala, N; Thuleau, A | 1 |
| Cao, C; Jin, L; Li, C; Li, S; Wang, X; Yuan, J; Zhu, C | 1 |
| Bernards, N; Beynel, A; Boisgard, R; Bouet, S; Buvat, I; Kuhnast, B; Tavitian, B; Thézé, B | 1 |
| Czarnota, GJ; El Kaffas, A; Falou, O; Fernandes, J; Giles, A; Hashim, A; Sadeghi-Naini, A; Tran, WT; Zhou, S | 1 |
| Choi, AR; Jung, MJ; Kim, JH; Yoon, S | 1 |
| Han, J; Hoff, BH; Kaspersen, SJ; Sundby, E | 1 |
| Ju, RJ; Li, XT; Li, XY; Lu, WL; Mu, LM; Shi, JF; Sun, MG; Yan, Y; Zeng, F; Zhao, Y | 1 |
| Chen, C; Li, G; Liu, FK; Liu, JY; Shen, L; Wu, GN; Wu, XY; Wu, ZF; Xu, H; Yao, XQ | 1 |
| Chao, MW; Chen, CS; Chou, CC; Chu, PC; Chuang, HC; Himmel, LE; Hsu, EC; Huang, HL; Kulp, SK; Shen, FH; Teng, CM; Tu, HJ | 1 |
| Chen, XW; Diehn, M; Sun, JG; Wang, J; Zhang, LP | 1 |
| Ding, J; Du, Y; Liu, JY; Tang, J; Zhou, Y | 1 |
| Bergh, J; Betsholtz, C; Foukakis, T; Genové, G; He, L; Landberg, G; Lindström, LS; Östman, A; Tobin, NP; Wennmalm, K | 1 |
| Cui, C; Hardwick, JC; Hawinkels, LJ; Heijkants, RC; Oudt, CH; Paauwe, M; Sier, CF; Theuer, CP; van Pelt, GW | 1 |
| Algenstaedt, P; Fiedler, W; Hansen-Algenstaedt, N; Rüther, W; Schaefer, C; Schroeder, M; Viezens, L; Wellbrock, J | 1 |
| Brown-Glaberman, U; Chalasani, P; Iannone, M; Livingston, R; Marron, M; Specht, J; Stopeck, AT | 1 |
| He, G; Huang, Y; Li, X; Luo, Y; Shen, P; Wu, F; Yang, L; Zhang, N; Zhao, Y | 1 |
| Ding, L; Meng, X; Song, S; Sun, B; Wu, S; Zhao, X | 1 |
| Byun, YS; Choi, KC; Go, RE; Jeon, SY; Jeung, EB; Kim, CW; Nam, KH | 1 |
| Buhari, SA; Chan, CW; Goh, BC; Hartman, M; Ho, J; Huang, Y; Iau, P; Jeyasekharan, AD; Lee, SC; Mogro, J; Ng, TC; Ow, SG; Pang, AS; Soh, TI; Sundar, R; Tan, CS; Tan, SH; Thng, CH; Wang, L; Wang, TT; Wong, AL; Zhang, B | 1 |
| El Ashal, G; Elgebaly, A; Ghanem, E; Menshawy, A; Negida, A; Omar, A; Osama, O | 1 |
| Bauer, C; Eisenhardt, SU; Günther, S; Jung, M; Kammerer, B; Kather, M; Lagies, S; Pan, D; Schlimpert, M; Schmidtkunz, K; Willmann, L | 1 |
| Andre, S; Braga, S; Brito, M; Cardoso, J; Dias, S; Orvalho, L; Passos-Coelho, JL; Pereira-Leal, JB; Salgado, L; Sanchez, P | 1 |
| Cheon, JH; Choi, AR; Kim, HS; Kim, JH; Woo, YH; Yoon, S | 1 |
| Alharbi, NO; Ansar, MA; Belali, OM; Korashy, HM | 1 |
| Amine, A; Guler, G; Kaplan, M; Kilic, T; Mandli, J; Ozsoz, M | 1 |
| Argyros, O; Bach, S; Baratte, B; Christoforidis, S; Daniilides, K; Evangelidis, T; Karamani, V; Kostakis, IK; Kouvari, E; Lougiakis, N; Marakos, P; Mikros, E; Papafotika, A; Pouli, N; Ruchaud, S; Skaltsounis, AL; Tamvakopoulos, C | 1 |
| Bicknell, R; Heath, VL; Wragg, JW | 1 |
| Ahn, JH; Chung, HC; Im, SA; Im, YH; Jung, KH; Kim, J; Kim, SB; Lee, KS; Park, HS; Ro, J; Sohn, BS; Song, HS | 1 |
| Nahleh, ZA | 1 |
| Jang, J; Ko, S | 1 |
| Lóopez-Marure, R; Massó, FA; Montaño, LF; Páez, A; Rodríguez, E; Sánchez, CA; Varela, E; Zapata, E | 1 |
| Borges, J; Esparís-Ogando, A; Ferreira, L; Ocaña, A; Pandiella, A; Rodríguez-Barrueco, R | 1 |
| Clohisy, DR; Dudek, AZ; Ericson, ME; Gallus, NJ; Jasinski, P; Terai, K; Zwolak, P | 1 |
| Kim, EA; Kwon, Y; Lee, KS; Park, IH; Ro, J | 1 |
| Altucci, L; Bonnet, S; Boulle, N; Bret, C; Cavailles, V; Duong, V; Duraffourd, C; Harmand, PO; Loubersac, J; Mai, A; Maudelonde, T; Valente, S | 1 |
| Hill, KL; Lipson, AC; Sheehan, JM | 1 |
| Busby, B; Covington, J; Gu, JW; Johnson, JW; Young, E | 1 |
| Li, H; Niu, R; Wu, J; Wu, M; Ying, G; Zhang, B; Zhang, N | 1 |
| Ishii, G; Jänne, PA; Minami, H; Mukohara, T; Nakatsura, T; Ogasawara, N; Park, JO; Saijo, N; Shimada, H; Shimomura, M; Wanikawa, R | 1 |
| Murugesan, S; Nadkarni, DH; Rayburn, ER; Velu, SE; Wang, W; Zhang, R | 1 |
| Cikotiene, I; León, LG; Padrón, JM; Pudziuvelyte, E; Ríos-Luci, C | 1 |
| Ang, BW; Cheng, CL; Chou, N; Lee, KM; Lee, SC; Wong, AL | 1 |
| Abbruzzese, A; Caraglia, M; Chiosi, E; Di Gesto, D; Illiano, F; Illiano, G; Marra, M; Naviglio, S; Romano, M; Sorrentino, A; Sorvillo, L; Spina, A | 1 |
| Cardoso, F; Senkus-Konefka, E | 1 |
| Bergh, J; Castany, R; Liljegren, A | 1 |
| Diaz, R; Hallahan, DE; Passarella, RJ; Phillips, JG; Wu, H; Zhou, L | 1 |
| Chen, D; Murugesan, S; Nadkarni, DH; Rayburn, ER; Velu, SE; Wang, W; Zhang, R | 1 |
| Chioni, AM; Djamgoz, MB; Grose, R; Shao, D | 1 |
| Antonini, G; Beria, I; Broggini, M; Caccuri, AM; Colombo, M; Federici, G; Geroni, C; Leboffe, L; MacArthur, R; Marchini, S; Mongelli, N; Mozzi, AF; Pezzola, S | 1 |
| Cataruozolo, PE; Chuang, E; Collier, M; Gowland, PA; Huang, X; Kern, KA; Kozloff, M; Miller, K; Starr, A; Verkh, L | 1 |
| Beyer, M; Classen, S; Debey-Pascher, S; Eggle, D; Kuhn, W; Lahn, M; Mallmann, MR; Muth, C; Pölcher, M; Rudlowski, C; Schultze, JL; Staratschek-Jox, A; Zander, T | 1 |
| Díaz-Rubio, E; López-Tarruella, S; Manzano, A; Martin, M; Puente, J | 1 |
| Guillén-Ponce, C; Mena, AC; Pulido, EG | 1 |
| Desplat, V; Fabre, SB; Gay, A; Godde, F; Guillon, J; Jarry, C; Macky, G; Massip, S; Moreau, S; Mossalayi, D; Thiolat, D | 1 |
| Fargnoli, J; Jordan, VC; Kim, HR; Klein-Szanto, AJ; Li, T; Oseni, S; Patel, RR; Pyle, JR; Ross, EA; Sengupta, S; Zhu, F | 1 |
| Aogi, K; Barrios, CH; Brickman, MJ; Ferrero, JM; Harbeck, N; Iwata, H; Kern, KA; Lee, SC; Liu, MC; Lugo-Quintana, R; Martin, M; Pivot, X; Tabei, T; Vanlemmens, L; Zhang, K | 1 |
| Gnant, M | 1 |
| Backer, JM; Backer, M; Blankenberg, FG; Hamby, CV; Levashova, Z; Pizzonia, J | 1 |
| Burstein, HJ; Dhakil, S; Fabian, C; Kozloff, M; Mayer, EL; Parmar, H; Patel, T; Qamar, R; Samant, M; Sundaram, S; Volterra, F | 1 |
| Banach-Petrosky, W; Biswas, S; Ganapathy, V; Ge, R; Grazioli, A; Kang, Y; Lonning, S; McPherson, J; Mundy, GR; Reiss, M; Xie, W; Yingling, JM | 1 |
| Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
| Chiosi, E; Di Gesto, D; Giordano, A; Illiano, F; Illiano, G; Naviglio, S; Spina, A | 1 |
| Browne, BC; Clynes, M; Crown, J; Duffy, MJ; O'Donovan, N; Slamon, D; Venkatesan, N | 1 |
| Canon, JL; De Greve, J; Focan, C; Fontaine, C; Martens, M; Paridaens, R; Squifflet, P; Vuylsteke, P; Wildiers, H; Wynendaele, W | 1 |
| Gu, JW; Huang, M; Miele, L; Tucker, KB; Wells, J; Young, E | 1 |
| Al-Tel, TH | 1 |
| Abrantes, AM; Beja, AM; Botelho, MF; Brito, AF; Laranjo, M; Paixão, JA; Pinho E Melo, TM; Silva, MR; Soares, MI | 1 |
| Chen, N; Donat, U; Gentschev, I; Hess, M; Krewer, B; Seubert, CM; Stritzker, J; Sturm, JB; Szalay, AA; Tietze, LF; von Hof, JM | 1 |
| Bareford, MD; Dent, P; Eulitt, P; Hossein, H; Martin, AP; Mitchell, C; Nephew, KP; Yacoub, A; Yang, C | 1 |
| Androulidaki, A; Arranz, A; Dermitzaki, E; Gomariz, RP; Margioris, AN; Mol, B; Rassouli, O; Ripoll, J; Stathopoulos, EN; Tsatsanis, C; Venihaki, M | 1 |
| Fratto, ME; Imperatori, M; Santini, D; Tomao, F; Tonini, G; Vincenzi, B | 2 |
| Andersen, JL; Andersson, M; Kamby, C; Nielsen, DL | 1 |
| Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
| Bensdorf, K; Guo, C; Gust, R; Huang, W; Liu, H; Liu, W; Qian, H; Rubner, G; Wang, Y; Wellner, A; Zhang, H; Zhang, Y; Zhou, J | 1 |
| Blay, JY; Coscas, Y; Khayat, D; Pivot, X; Soria, JC; Spano, JP | 1 |
| Addeo, R; Caraglia, M | 1 |
| Handal, J; Kwok, SC; Samuel, SP | 1 |
| Bharathi, EV; Dastagiri, D; Kamal, A; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Reddy, JS; Reddy, MK; Sarma, P; Srikanth, YV | 1 |
| Brower, SL; Ervin, PR; Hancher, LM; Suchy, SL; Wang, D | 1 |
| Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW | 1 |
| Gong, P; Lv, Y; Wang, S; Zhang, G; Zhang, N; Zhao, Y | 1 |
| Boerner, JL; Bohin, N; Ge, Y; Irwin, ME; Mueller, KL | 1 |
| Bensdorf, K; Guo, C; Gust, R; Liu, H; Liu, W; Liu, Y; Zhou, J | 1 |
| Cortes, J; Roché, H | 1 |
| Backer, JM; Backer, MV; Blankenberg, FG; Goris, MG; Hamby, CV; Levashova, Z | 1 |
| Gust, R; Schäfer, A; Strauss, M; Wellner, A; Wolber, G | 2 |
| Kerbel, RS | 1 |
| Anderson, L; Bhattacharya, S; Bose, N; Fraser, E; Graham, K; Lumsden, G; McClue, L; Robertson, L; Tho, LM; Yosef, H | 1 |
| Akhurst, RJ; Babb, JS; Barcellos-Hoff, MH; Bouquet, F; Demaria, S; DeWyngaert, JK; Formenti, SC; Hann, B; Lonning, SM; Pal, A; Pilones, KA | 1 |
| Dhasarathy, A; Mav, D; Phadke, D; Shah, RR; Wade, PA | 1 |
| Amiri-Kordestani, L; Bates, SE; Fojo, T | 1 |
| Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L | 1 |
| Christensen, JG; Lappin, PB; Lee, JH; Shojaei, F; Simmons, BH | 1 |
| Chresta, CC; Cosulich, S; Crafter, C; Cross, D; Davies, BR; Dudley, P; Gao, B; Greenwood, H; Ji, Q; Lane, C; Li, J; Luke, R; Maynard, J; Ogilvie, D; Page, K; Pass, M; Ricketts, SA; Watson, R; Yates, J; Yu, DH; Zhang, J | 1 |
| Clouthier, SG; Conley, SJ; Gheordunescu, E; Heath, AN; Kakarala, P; Korkaya, H; Newman, B; Wicha, MS | 1 |
| Bergh, J; Bischoff, J; Bondarenko, IM; Chan, A; Cortes, J; Delaloge, S; Giorgetti, C; Greil, R; Huang, X; Kern, KA; Lichinitser, MR; Liljegren, A; Lortholary, A; Makhson, AN; Voytko, NL | 1 |
| Floersheimer, A; Furet, P; Lang, M; Stauffer, F | 1 |
| Awada, A; Bergh, J; Cardoso, F; Gianni, L; Giorgetti, C; Huang, X; Kern, KA; Liljegren, A; Mariani, G; Verkh, L; Viganò, L | 1 |
| Beenakker, JW; Cui, C; Danen, EH; Ghotra, VP; He, S; Lamers, GE; Meijer, AH; Snaar-Jagalska, BE; Spaink, HP | 1 |
| Aogi, K; Arioka, H; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Sato, Y; Takatsuka, Y; Toi, M; Tokuda, Y | 1 |
| Carmody, LC; Dandapani, S; Feng, Y; Fernandez, C; Forbeck, E; Germain, AR; Gupta, PB; Lander, ES; Lewis, TA; Morgan, B; Munoz, B; Nag, PP; Palmer, M; Perez, JR; Schreiber, SL; Ting, A; VerPlank, L | 1 |
| Cowell, JK; Ghoshal, P; Lesoon, LA; Teng, Y | 1 |
| Aogi, K; Arioka, H; Fujii, H; Fujiwara, Y; Inoue, K; Ito, Y; Iwata, H; Saeki, T; Suzuki, Y; Takatsuka, Y; Toi, M; Tokuda, Y; Watanabe, T | 1 |
| Ekyalongo, RC; Fujiwara, Y; Funakoshi, Y; Kataoka, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H | 1 |
| Kaklamani, V; Raffin, M; Reddy, S | 1 |
| Airley, R | 1 |
| Carley, W; DePrimo, SE; Harmon, CS; Huang, X; Kern, KA; Keyvanjah, K | 1 |
| Carmody, LC; Germain, AR; Muñoz, B; Nag, PP; Palmer, MA; Perez, JR; VerPlank, L | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, H; Tang, Y | 1 |
| Aldrighetti, D; Amadori, D; Bouko, Y; Canon, JL; Cardoso, F; Dirix, L; Giorgetti, C; Kern, KA; Machiels, JP; Usari, T; Verkh, L | 1 |
| Brickman, MJ; Citrin, DL; Dees, EC; Healey, P; Kern, KA; Li, S; Myers, SD; Paolini, J; Wang, Z; Yardley, DA | 1 |
| Ballot, J; Browne, BC; Crown, J; Duffy, MJ; Eustace, AJ; Kennedy, J; Kennedy, S; Larkin, A; Madden, S; Mahgoub, T; McDermott, MS; O'Brien, NA; O'Donovan, N; Pedersen, K; Sclafani, F | 1 |
| Ali, MM; El Diwani, HI; Galal, SA; Kerwin, SM; Li, J; Omar, MA; Ramadan, RA; Shaker, YM; Tokuda, H | 1 |
| Ebiike, H; Kawada, H; Morikami, K; Nakamura, M; Ogawa, K; Ohwada, J; Shimma, N; Tsukazaki, M; Tsukuda, T; Yoshida, M; Yoshinari, K | 1 |
| El Gendy, MA; El-Kadi, AO; Korashy, HM; Maayah, ZH | 1 |
| Botelho, MF; Brito, AF; Laranjo, M; Paixão, JA; Pinho e Melo, TM; Soares, MI | 1 |
| Bauerschlag, D; Bender, S; Glüer, CC; Hamann, S; Jonat, W; Kalthoff, H; Loermann, D; Lorenzen, AC; Rösel, F; Schem, C; Tiwari, S | 1 |
| Abu-Asab, M; Clarke, R; Cook, KL; Schwartz-Roberts, JL; Shajahan, AN; Wärri, A | 1 |
| Beerman, TA; Chang, AY; Dervan, PB; Dziegielewski, J; Wang, YD | 1 |
| Abrams, TJ; Cherrington, JM; Colombo, T; Holway, VW; Lee, LB; Murray, LJ; Pesenti, E; Pryer, NK | 1 |
| Inaba, T; Lee, C; Patterson, AV; Ramji, S; Riddick, DS | 1 |
| Abrams, TJ; Brassard, JA; Cherrington, JM; Hong, W; Keast, PK; Long, KR; Murray, LJ; Ngai, TJ; O'Farrell, AM; Olson, LM; Pryer, NK | 1 |
| Mück, AO; Seeger, H; Wallwiener, D | 1 |
| Appavu, C; Berrodin, T; Chippari, S; Chopra, R; Cohen, J; Fensome, A; Li, S; Lyttle, CR; Olland, AM; Unwalla, RJ; Wilhem, J; Winneker, RC; Wrobel, J; Zhang, P; Zhang, Z; Zhu, Y | 1 |
| Cohen, J; Fensome, A; Kern, J; Terefenko, EA; Winneker, R; Wrobel, J; Zhang, P; Zhang, Z; Zhu, Y | 1 |
| Nagy, A; Schally, AV | 1 |
| Atkins, GJ; Campiani, G; Fleeton, M; Gowda, C; Greene, LM; Lawler, M; Mulligan, J; Nacci, V; Sheahan, BJ; Williams, DC; Zisterer, DM | 1 |
| Marian, B; Nohl, H; Rohr-Udilova, N; Stolze, K | 1 |
| Baldwin, SJ; Kotyk, JJ; Pagel, MD; Rader, RK | 1 |
| Alamanou, M; Angelucci, A; Bologna, M; Del Fattore, A; Fabbro, D; Fortunati, D; Recchia, I; Rucci, N; Susa, M; Teti, A | 1 |
| Saito, Y; Suzuki, Y; Tokuda, Y | 1 |
| Graziani, G; Muzi, A; Navarra, P; Pozzoli, G; Tentori, L; Tringali, G; Vergati, M | 1 |
| Burstein, HJ; Rugo, HS; Sledge, GW | 1 |
| Li, H; Weinstein, IB | 1 |
| Berger, M; Lipton, A; Planas-Silva, MD; Viallet, J; Witkoski, A; Witters, LM | 1 |
| Arthur, CR; Cabot, MC; Gewirtz, DA; Gupton, JT; Kellogg, GE; Newsham, IF; Yeudall, WA | 1 |
| Hayes, DF; Miller, K; Sledge, G | 1 |
| Adams, VR; Leggas, M | 1 |
| Abdul-Karim, FW; Dowlati, A; Duerk, J; Fu, P; Hanks, S; Hartman, P; Hoppel, C; Ivy, P; Jesberger, JA; Lewin, J; McCrae, K; Overmoyer, B; Persons, M; Radivoyevitch, T; Remick, SC; Robertson, K; Shenk, R; Silverman, P; Wasman, JK; Ziats, NP | 1 |
| Polyzos, A | 1 |
| Adams, BJ; Baum, CM; Bello, CL; Burstein, HJ; Cobleigh, MA; DePrimo, SE; Eisenberg, PD; Elias, AD; Lehman, M; Miller, KD; Rugo, HS; Wolff, AC | 1 |
| Anderson, WK | 1 |
| Anderson, WK; McPherson, HL; New, JS; Rick, AC | 1 |
| Abraham, I; McCroskey, MC; Sampson, KE | 1 |
| Armatis, P; Groot, K; Halmos, G; Horvath, J; Jungwirth, A; Kovacs, M; Miyazaki, M; Nagy, A; Schally, AV; Szepeshazi, K; Zarandi, M | 1 |
| Groot, K; Halmos, G; Hebert, F; Kahán, Z; Nagy, A; Schally, AV; Sun, B | 1 |
| Jonkers, GH | 1 |
| Hioki, K; Hirata, H; Kiyozuka, Y; Takemoto, H; Tanaka, K; Tsubura, A; Uemura, Y; Yamamoto, C; Yamamoto, D | 1 |
| Arencibia, JM; Groot, K; Halmos, G; Kahán, Z; Nagy, A; Schally, AV | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Fry, DW; Slichenmyer, WJ | 1 |
| Bland, KI; Filardo, EJ; Frackelton, AR; Quinn, JA | 1 |
| Campiani, G; Hyland, E; Mc Gee, MM; Nacci, V; Ramunno, A; Zisterer, DM | 1 |
| Baden, T; Hioki, K; Hirata, H; Inoue, K; Inubushi, T; Kamato, K; Morikawa, S; Nakai, K; Takemoto, H; Tanaka, K; Yamamoto, C; Yamamoto, D | 1 |
| Hynes, NE; Lane, HA; Motoyama, AB | 1 |
20 review(s) available for pyrroles and Breast Neoplasms
| Article | Year |
|---|---|
"The emerging role of capivasertib in breast cancer".
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Fulvestrant; Humans; Mutation; Paclitaxel; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2022 |
Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Female; Heterografts; Humans; Indoles; Mice; Mice, Transgenic; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Neoplasm Transplantation; Pyrroles; Species Specificity; Sunitinib; Survival Analysis; Treatment Outcome | 2013 |
Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Indoles; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib | 2016 |
Molecularly targeted therapy in breast cancer: the new generation.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Design; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Receptors, Estrogen; Sunitinib | 2008 |
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Renal Cell; Colonic Neoplasms; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2010 |
[Neoadjuvant treatment and breast conserving surgery - a success of clinical research in breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Indoles; Mastectomy, Segmental; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Protein-Tyrosine Kinases; Pyrroles; Radiotherapy; Randomized Controlled Trials as Topic; Sunitinib | 2010 |
New perspectives: role of sunitinib in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Indoles; Neoplasm Metastasis; Pyrroles; Sunitinib | 2010 |
Antiangiogenic therapy for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Added value of molecular targeted agents in oncology.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Indoles; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, ErbB-2; Rituximab; Sunitinib; Trastuzumab | 2011 |
Docetaxel combined with targeted therapies in metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Indoles; Lapatinib; Pyrroles; Quinazolines; Sunitinib; Taxoids; Trastuzumab | 2012 |
Reappraising antiangiogenic therapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Confounding Factors, Epidemiologic; Cross-Over Studies; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Interferon-gamma; Neoplasms; Patient Selection; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Sunitinib; Treatment Outcome | 2011 |
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Endometrial Neoplasms; Epithelial Cells; Female; Gonadotropin-Releasing Hormone; Humans; Male; Ovarian Neoplasms; Prostatic Neoplasms; Pyrroles; Receptors, LHRH | 2005 |
[Molecular-targeted agents in breast cancer].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Indoles; Lapatinib; Middle Aged; Paclitaxel; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab | 2006 |
The role of angiogenesis inhibition in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Multicenter Studies as Topic; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2006 |
Angiogenesis as targeted breast cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Topics: Age Factors; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lactation; Lung Neoplasms; Neuroendocrine Tumors; Pregnancy; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2007 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2001 |
30 trial(s) available for pyrroles and Breast Neoplasms
| Article | Year |
|---|---|
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomar
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptors, Estrogen | 2022 |
Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Estrogen Receptor alpha; Female; Humans; Ki-67 Antigen; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction; Tissue Distribution; Treatment Outcome | 2020 |
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Pyrroles; Receptors, Estrogen; Salvage Therapy; Survival Rate | 2020 |
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Estrogen Receptor alpha; Female; Fulvestrant; Genotype; Humans; Middle Aged; Molecular Targeted Therapy; Mutation; Prospective Studies; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome | 2020 |
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; National Cancer Institute (U.S.); Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; United States | 2021 |
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Estrogen; Survival Rate | 2019 |
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atorvastatin; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Combined Modality Therapy; Female; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ki-67 Antigen; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Prospective Studies; Pyrroles; Sunitinib; Young Adult | 2013 |
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pyrroles; Sunitinib; Trastuzumab; Treatment Outcome | 2014 |
Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Indoles; Middle Aged; Oxindoles; Propionates; Pyrroles; Taxoids | 2014 |
Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Hypothyroidism; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Survival Rate; Thyrotropin; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2014 |
A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Pyrroles; Sunitinib | 2015 |
Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Hypoxia; Cell Proliferation; Docetaxel; Female; Gene Expression Profiling; Humans; Indoles; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prospective Studies; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2015 |
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Contrast Media; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Indoles; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Preoperative Period; Pyrroles; Sunitinib; Treatment Outcome | 2016 |
Does Hypoxic Response Mediate Primary Resistance to Sunitinib in Untreated Locally Advanced Breast Cancer?
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Pyrroles; Sunitinib; Treatment Outcome; Tumor Hypoxia | 2017 |
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genes, erbB-2; Humans; Indoles; Kaplan-Meier Estimate; Pyrroles; Sunitinib | 2010 |
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Belgium; Breast Neoplasms; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Middle Aged; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Time Factors; Treatment Outcome | 2010 |
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis | 2011 |
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Male; Mice; Mice, Nude; Mice, SCID; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Female; Humans; Indoles; International Agencies; Middle Aged; Prospective Studies; Pyrroles; Receptor, ErbB-2; Sunitinib; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Docetaxel; Drug Administration Schedule; Drug Interactions; Feasibility Studies; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Treatment Outcome | 2012 |
A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Indoles; Middle Aged; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Drug Administration Schedule; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Treatment Outcome | 2012 |
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Humans; Indoles; Infusions, Intravenous; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pyrroles; Receptor, ErbB-2; Sunitinib; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Middle Aged; Nausea; Pyrroles; Sunitinib; Thrombocytopenia; Treatment Outcome | 2012 |
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Doxorubicin; Female; Humans; Indoles; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neovascularization, Pathologic; Pyrroles; Treatment Outcome | 2007 |
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Female; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sunitinib | 2008 |
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Carcinoma; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Indoles; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Survival Rate; Taxoids | 2008 |
201 other study(ies) available for pyrroles and Breast Neoplasms
| Article | Year |
|---|---|
AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3'-diindolylmethane in human breast cancer cells.
Topics: AC133 Antigen; Active Transport, Cell Nucleus; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Forkhead Box Protein O3; Humans; Indoles; MCF-7 Cells; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction | 2021 |
The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
Topics: Animals; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colchicine; Drug Design; Female; Mice; Mice, Nude; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tubulin Modulators; Xenograft Model Antitumor Assays | 2021 |
Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Protein Kinase C; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2022 |
Endoplasmic Reticulum Stress-Induced Apoptotic Effects of Novel 1-Pyrroline (3,4-Dihydro-2H-pyrrole) Derivatives on Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Endoplasmic Reticulum Stress; Female; Humans; Pyrroles; Reactive Oxygen Species | 2022 |
A Simple and Low-Cost Electrochemical Immunosensor for Ultrasensitive Determination of Calreticulin Biomarker in Human Serum.
Topics: Biomarkers; Biosensing Techniques; Breast Neoplasms; Calreticulin; Electrochemical Techniques; Electrodes; Female; Graphite; Humans; Immunoassay; Polymers; Pyrroles; Reproducibility of Results | 2023 |
Capivasertib Doubles PFS in Some Breast Cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Fulvestrant; Humans; Pyrimidines; Pyrroles; Receptor, ErbB-2 | 2023 |
Polypyrrole/carbon dot nanocomposite as an electrochemical biosensor for liquid biopsy analysis of tryptophan in the human serum of normal and breast cancer women.
Topics: Biosensing Techniques; Breast Neoplasms; Carbon; Electrochemical Techniques; Electrodes; Female; Graphite; Humans; Nanocomposites; Polymers; Pyrroles; Tryptophan | 2023 |
Quinoxalinone substituted pyrrolizine (4h)-induced dual inhibition of AKT and ERK instigates apoptosis in breast and colorectal cancer by modulating mitochondrial membrane potential.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Membrane Potential, Mitochondrial; Mice; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Proto-Oncogene Proteins c-akt; Pyrroles; Quinoxalines | 2023 |
Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
Topics: Animals; Breast Neoplasms; Disease Models, Animal; Female; Humans; Pyrazoles; Pyrimidines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor | 2023 |
Antiangiogenic Effect of Isomalyngamide A Riboside CY01 in Breast Cancer Cells
Topics: Amides; Angiogenesis Inhibitors; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Diamines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ethylenediamines; Fatty Acids; Female; Glycosides; Glycosylation; Human Umbilical Vein Endothelial Cells; Humans; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Ribose; Signal Transduction; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cyclophilin A; Female; Humans; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Mammary Neoplasms, Experimental; MAP Kinase Kinase Kinases; Mice; Mitogen-Activated Protein Kinase Kinase Kinase 11; NFATC Transcription Factors; Phosphorylation; Primary Cell Culture; Protein Kinase Inhibitors; Pyridines; Pyrroles; T-Lymphocytes, Cytotoxic; Tumor Escape | 2020 |
PdpaMn inhibits fatty acid synthase-mediated glycolysis by down-regulating PI3K/Akt signaling pathway in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Fatty Acid Synthase, Type I; Female; Glycolysis; Humans; Manganese Compounds; Mice, Inbred BALB C; Organometallic Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Cell-Penetrating Peptide-Conjugated BF
Topics: Antineoplastic Agents; Biocompatible Materials; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Infrared Rays; Molecular Structure; Optical Imaging; Photothermal Therapy; Pyrroles; Spectroscopy, Near-Infrared; Structure-Activity Relationship | 2020 |
Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lim Kinases; MAP Kinase Signaling System; Mice; p21-Activated Kinases; Phosphorylation; Pyrazoles; Pyrroles; Thiazoles; Xenograft Model Antitumor Assays | 2020 |
Persistent luminescence-polypyrrole nanocomposite for dual-modal imaging and photothermal therapy of mammary cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Humans; Luminescence; Nanocomposites; Nanoparticles; Phototherapy; Photothermal Therapy; Polymers; Pyrroles; Theranostic Nanomedicine | 2021 |
Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.
Topics: Administration, Inhalation; Administration, Intravenous; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Paclitaxel; Phosphorylation; Pyrroles; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Tumor Microenvironment; Tumor-Associated Macrophages | 2020 |
Multifunctional HNT@Fe
Topics: Breast Neoplasms; Doxorubicin; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Polymers; Pyrroles | 2020 |
X-ray Crystal Structure-Guided Design and Optimization of 7
Topics: Administration, Oral; Animals; Binding Sites; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Female; Half-Life; Humans; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Structure-Activity Relationship; Transplantation, Heterologous | 2021 |
4-Propargyl-substituted 1H-pyrroles induce apoptosis and autophagy via extracellular signal-regulated signaling pathway in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Epithelial Cells; Female; Humans; MAP Kinase Signaling System; Pyrroles; Signal Transduction; Structure-Activity Relationship | 2021 |
Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase-2 inhibitor and toceranib phosphate.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Cyclooxygenase 2 Inhibitors; Cyclophosphamide; Dog Diseases; Dogs; Female; Indoles; Pyrroles; Retrospective Studies | 2022 |
Cytostatic Effect of a Novel Mitochondria-Targeted Pyrroline Nitroxide in Human Breast Cancer Lines.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytostatic Agents; Female; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Nitrogen Oxides; Pyrroles; Reactive Oxygen Species; Triple Negative Breast Neoplasms | 2021 |
Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Oxindoles; Pyrroles; Sunitinib; Tumor Burden; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Somatomedin; Tamoxifen; Trastuzumab; Xenograft Model Antitumor Assays | 2017 |
Targeted co-delivery of polypyrrole and rapamycin by trastuzumab-conjugated liposomes for combined chemo-photothermal therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Humans; Liposomes; Photochemotherapy; Polymers; Pyrroles; Receptor, ErbB-2; Sirolimus; Trastuzumab | 2017 |
Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells.
Topics: Autocrine Communication; Axitinib; Breast Neoplasms; Cathepsin G; Cell Aggregation; Female; Humans; Imidazoles; Indazoles; Indoles; Insulin-Like Growth Factor I; MCF-7 Cells; Phosphorylation; Pyrazines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Small Molecule Libraries; Sunitinib | 2017 |
DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors.
Topics: Adenosine Triphosphate; Binding, Competitive; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Replication; Female; Humans; Phosphorylation; Piperidones; Protein Serine-Threonine Kinases; Pyrimidinones; Pyrroles | 2017 |
Breast cancer cell obatoclax response characterization using passivated-electrode insulator-based dielectrophoresis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cell Size; Drug Resistance, Neoplasm; Electrodes; Electrophoresis; Estrogen Antagonists; Female; Humans; Indoles; MCF-7 Cells; Microfluidic Analytical Techniques; Pyrroles | 2017 |
Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
Topics: Animals; Antibodies, Monoclonal; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Haplorhini; Humans; Immunoconjugates; Male; Mice; Prostatic Neoplasms; Pyrroles; Rats; Therapeutic Index; Trastuzumab; Xenograft Model Antitumor Assays | 2017 |
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Enlargement; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Female; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptor, IGF Type 1; src-Family Kinases | 2017 |
Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-κB Signaling Pathways.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; DNA Repair; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Indoles; NF-kappa B; Pyrroles; Sunitinib; Tumor Cells, Cultured | 2017 |
Pyrrolobenzodiazepine Dimer Antibody-Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dimerization; Female; Humans; Immunoconjugates; Mice; Models, Molecular; Neoplasms; Pyrroles; Receptor, ErbB-2; Sialic Acid Binding Ig-like Lectin 2 | 2017 |
The Strategy of PIKing a Target: What Is AKTually Most Effective?
Topics: Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles | 2018 |
Further Developments of the Phenyl-Pyrrolyl Pentane Series of Nonsteroidal Vitamin D Receptor Modulators as Anticancer Agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Breast Neoplasms; Calcium; Cell Cycle; Drug Screening Assays, Antitumor; Female; HL-60 Cells; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Molecular Mimicry; Pentanes; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Calcitriol; Structure-Activity Relationship; Vitamin D; Vitamins | 2018 |
Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase Cell Cycle Checkpoints; Humans; Mice; Mice, Transgenic; Morpholines; Phosphorylation; Piperazines; Pyrroles; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2018 |
E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer.
Topics: Animals; Autocrine Communication; Breast Neoplasms; Cadherins; Carcinoma, Lobular; Class I Phosphatidylinositol 3-Kinases; Female; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Mice; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Signal Transduction | 2018 |
Targeting tyrosine kinase: Development of acridone - pyrrole - oxindole hybrids against human breast cancer.
Topics: Acridones; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Oxindoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Structure-Activity Relationship | 2019 |
Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer.
Topics: Acetylation; Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase 6; Female; Forkhead Box Protein O3; Gene Expression Regulation; Heterocyclic Compounds, 3-Ring; Humans; Mice; Mice, Nude; Nuclear Proteins; Oxadiazoles; Promoter Regions, Genetic; Protein Binding; Protein Domains; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Sirtuins; Transcription Factors | 2018 |
The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo.
Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Colchicine; Female; Humans; Mice, Inbred Strains; Neovascularization, Pathologic; Pyrimidines; Pyrroles; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2019 |
A new pyrrole based small molecule from Tinospora cordifolia induces apoptosis in MDA-MB-231 breast cancer cells via ROS mediated mitochondrial damage and restoration of p53 activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Fragmentation; Female; G1 Phase Cell Cycle Checkpoints; Humans; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mice; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reactive Oxygen Species; Survival Rate; Tinospora; Tumor Suppressor Protein p53 | 2019 |
Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.
Topics: Animals; Antibodies; Arginase; Breast Neoplasms; Cell Line, Tumor; Cytokines; Disease Models, Animal; Female; Immunoconjugates; Immunotherapy; Immunotoxins; Macrophages; Mice; Mice, Nude; Monocytes; Neoplasms; Neutrophils; Piperidines; Pyrimidines; Pyrroles; RNA, Messenger; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Human Umbilical Vein Endothelial Cells; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phosphorylation; Piperazines; Pyrroles; Random Allocation; Rats; Receptors, Fibroblast Growth Factor; Thiophenes; Xenograft Model Antitumor Assays | 2019 |
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Progression-Free Survival; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2019 |
Synthesis and anti-breast cancer activity of novel indibulin related diarylpyrrole derivatives.
Topics: Acetamides; Animals; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Humans; Indoles; MCF-7 Cells; Mice; Molecular Structure; NIH 3T3 Cells; Pyrroles; Tubulin | 2019 |
Novel hyaluronic acid-modified temperature-sensitive nanoparticles for synergistic chemo-photothermal therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Contrast Media; Docetaxel; Drug Carriers; Drug Liberation; Female; Fluorescent Dyes; Humans; Hyaluronic Acid; Infrared Rays; Injections, Intravenous; Lung; Lung Neoplasms; Mice, Inbred BALB C; Nanoparticles; Particle Size; Phospholipids; Photoacoustic Techniques; Polymers; Pyrroles; Temperature; Theranostic Nanomedicine | 2019 |
Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide.
Topics: Animals; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Mice; Nitriles; Phenylthiohydantoin; Pyrroles; Pyrrolidines; Signal Transduction; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2019 |
Discovery of Rho-kinase inhibitors by docking-based virtual screening.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cerebral Hemorrhage; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; HeLa Cells; Heptanoic Acids; Humans; Lung Neoplasms; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Multiple Myeloma; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; Zebrafish | 2013 |
Pak1 kinase links ErbB2 to β-catenin in transformation of breast epithelial cells.
Topics: Animals; Apoptosis; beta Catenin; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Epithelial Cells; Humans; Mice; Mice, Inbred ICR; Mice, Knockout; Mice, SCID; Mice, Transgenic; p21-Activated Kinases; Pyrazoles; Pyrroles; Receptor, ErbB-2; RNA Interference; Xenograft Model Antitumor Assays | 2013 |
Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Gamma Rays; Humans; Indoles; Microarray Analysis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line; Cell Proliferation; Female; Humans; JNK Mitogen-Activated Protein Kinases; Mammary Glands, Human; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; MCF-7 Cells; Neoplasm Proteins; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Stability; Pyrroles; Quinolones; Transforming Growth Factor beta2; Ubiquitination; Up-Regulation | 2013 |
A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Indoles; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Sunitinib; Time Factors; Treatment Outcome | 2013 |
Glycosylation enhances the anti-migratory activities of isomalyngamide A analogs.
Topics: Adenocarcinoma; Amides; Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glycosylation; Humans; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
[Clinical observation of sunitinib treatment for refractory advanced breast cancer ulcer].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Ulcer | 2013 |
Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Insulin-Like Growth Factor I; Ligands; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Receptor, Insulin; Receptors, Estrogen; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists.
Topics: Animals; Benzopyrans; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Female; Half-Life; Humans; Inhibitor of Apoptosis Proteins; Mice; Molecular Dynamics Simulation; Protein Structure, Tertiary; Pyrazines; Pyrroles; RNA, Messenger; Stereoisomerism; Transplantation, Heterologous; Tumor Necrosis Factor-alpha | 2013 |
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Topics: Animals; Anoikis; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Brain Neoplasms; Breast Neoplasms; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; ErbB Receptors; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Indoles; Lapatinib; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Estrogen Receptor alpha; Female; Flow Cytometry; Humans; Indoles; Mammary Neoplasms, Experimental; MAP Kinase Signaling System; MCF-7 Cells; Mice; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Random Allocation; Signal Transduction; Sunitinib; Tamoxifen; Transcription Factor AP-2 | 2014 |
Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Renal Cell; Cell Line, Tumor; Endothelial Cells; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Sunitinib effects on the radiation response of endothelial and breast tumor cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Mice; Mice, SCID; Pyrroles; Radiation Tolerance; Sunitinib; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2014 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Clinical outcome of Turkish metastatic breast cancer patients with currently available treatment modalities--single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Neoplasm Metastasis; Postmenopause; Premenopause; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Sunitinib; Survival Rate; Trastuzumab; Turkey; Young Adult | 2014 |
Cyclic marinopyrrole derivatives as disruptors of Mcl-1 and Bcl-x(L) binding to Bim.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Blotting, Western; Breast Neoplasms; Catalysis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indicators and Reagents; Isomerism; Magnetic Resonance Spectroscopy; Marine Toxins; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Protein Binding; Proto-Oncogene Proteins; Pyrroles; Spectrophotometry, Ultraviolet; Structure-Activity Relationship | 2014 |
Targeting triple-negative breast cancer cells with 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Death; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Structure; Pyrroles; Structure-Activity Relationship; Thiazoles; Tumor Cells, Cultured | 2014 |
Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis.
Topics: Animals; Atorvastatin; Breast; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Female; Heptanoic Acids; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Oxidation-Reduction; Polyethylene Glycols; Pyrroles; Vitamin E | 2014 |
Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Gene Expression; Humans; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Signal Transduction; STAT3 Transcription Factor; Transcription Factors; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
JARID1B is a luminal lineage-driving oncogene in breast cancer.
Topics: Breast Neoplasms; CCCTC-Binding Factor; Cell Growth Processes; Cell Line, Tumor; Cell Lineage; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; MCF-7 Cells; Mutation; Nuclear Proteins; Oncogenes; Promoter Regions, Genetic; Pyrazoles; Pyrroles; Repressor Proteins; RNA, Small Interfering; Transfection; Transforming Growth Factor beta | 2014 |
Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
Topics: Atorvastatin; Benzophenones; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Transferases; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Androgen; RNA, Messenger; Transcriptional Activation; Triple Negative Breast Neoplasms | 2014 |
Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration.
Topics: Atorvastatin; Benzamides; Breast Neoplasms; Cell Movement; Cell Proliferation; Female; HEK293 Cells; Heptanoic Acids; Hippo Signaling Pathway; Humans; MCF-7 Cells; Prenylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2015 |
Novel sulfonamides bearing pyrrole and pyrrolopyrimidine moieties as carbonic anhydrase inhibitors: Synthesis, cytotoxic activity and molecular modeling.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Carbonic Anhydrase I; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Pyrroles; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured | 2014 |
Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Female; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinase Kinase 11; Neoplasm Transplantation; Protein Kinase Inhibitors; Pyridines; Pyrroles; Transplantation, Heterologous | 2014 |
Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Dopamine; Drug Resistance, Neoplasm; Drug Synergism; Female; Flow Cytometry; Humans; Indoles; Microscopy, Fluorescence; Neoplastic Stem Cells; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Identification of two benzopyrroloxazines acting as selective GPER antagonists in breast cancer cells and cancer-associated fibroblasts.
Topics: Binding, Competitive; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Indicators and Reagents; Ligands; Models, Molecular; Molecular Conformation; Pyrroles; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction | 2015 |
Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Indoles; Middle Aged; Neoplasm Staging; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sunitinib; Tumor Cells, Cultured | 2015 |
Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.
Topics: Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Everolimus; Female; Humans; Immunosuppressive Agents; Neoplasm Metastasis; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Dosage; Humans; Indoles; Keratins; MCF-7 Cells; Neoplastic Cells, Circulating; Pyrroles; Spheroids, Cellular; Sunitinib; Treatment Outcome; Tumor Cells, Cultured | 2015 |
Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Female; Fibronectins; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Pyrazoles; Pyrroles; RNA, Messenger; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Transforming Growth Factor beta1; Transforming Growth Factor beta2; Triple Negative Breast Neoplasms; Vimentin; Wound Healing | 2015 |
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; MCF-7 Cells; Mice; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2015 |
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Fulvestrant; Gene Expression Profiling; Humans; Mice; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrimidines; Pyrroles; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Transcriptional Activation; Xenograft Model Antitumor Assays | 2015 |
Urocortin attenuates TGFβ1-induced Snail1 and slug expressions: inhibitory role of Smad7 in Smad2/3 signaling in breast cancer cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Peptide Fragments; Pyrimidines; Pyrroles; Signal Transduction; Smad2 Protein; Smad3 Protein; Smad7 Protein; Snail Family Transcription Factors; Transcription Factors; Transforming Growth Factor beta1; Urocortins | 2015 |
Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; C-Reactive Protein; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factors; Humans; Indoles; Interleukin-6; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Taxoids; Vascular Endothelial Growth Factor A | 2016 |
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Misonidazole; Positron-Emission Tomography; Pyrroles; Sunitinib | 2015 |
Assessment of tumor response to radiation and vascular targeting therapy in mice using quantitative ultrasound spectroscopy.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Chemoradiotherapy; Fibroblast Growth Factors; Humans; Immunohistochemistry; Indoles; Mice, SCID; Neoplasm Transplantation; Oxygen; Pyrroles; Spectrum Analysis; Sunitinib; Treatment Outcome; Ultrasonography | 2015 |
Co-treatment of Salinomycin Sensitizes AZD5363-treated Cancer Cells Through Increased Apoptosis.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Pyrans; Pyrimidines; Pyrroles; S Phase | 2015 |
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Topics: Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Lung Neoplasms; Ovarian Neoplasms; Pyrimidines; Pyrroles | 2015 |
A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diffusion; Female; Indoles; Liposomes; Materials Testing; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Nanocomposites; Neoplasm Invasiveness; Particle Size; Pyrroles; Sunitinib; Surface Properties; Treatment Outcome; Tumor Burden; Vinblastine; Vinorelbine | 2015 |
Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Aorta; Breast Neoplasms; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Female; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Isoflavones; Male; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Rats, Sprague-Dawley; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2015 |
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Topics: Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Depsipeptides; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Neoplastic Stem Cells; Nylons; Phenylbutyrates; Protein Stability; Pyrroles; Receptor, Notch1; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Spheroids, Cellular; Transplantation, Heterologous | 2016 |
Yap1 promotes the survival and self-renewal of breast tumor initiating cells via inhibiting Smad3 signaling.
Topics: Adaptor Proteins, Signal Transducing; Animals; Breast Neoplasms; Cell Cycle Proteins; Estrogen Receptor alpha; Female; Humans; Isoquinolines; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Knockout; Neoplastic Stem Cells; Phosphoproteins; Phosphorylation; Pyridines; Pyrroles; Smad3 Protein; Transcription Factors; Transforming Growth Factor beta; Wnt1 Protein; YAP-Signaling Proteins | 2016 |
The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells.
Topics: Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Breast Neoplasms; Catechin; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Immunoenzyme Techniques; Indoles; Insulin Receptor Substrate Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Prognosis; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sunitinib; Tea; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2016 |
An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.
Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cohort Studies; Docetaxel; Female; Gene Expression; Genomics; Hemangioendothelioma; Hormones; Humans; Indoles; Microvessels; Middle Aged; Prognosis; Pyrroles; Sunitinib; Taxoids; Transcription, Genetic | 2016 |
Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.
Topics: Animals; Antibodies, Monoclonal; Breast Neoplasms; Endoglin; Female; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Smad1 Protein; Vascular Endothelial Growth Factor A; Zebrafish | 2016 |
Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Breast Neoplasms; Female; Indoles; Mice; Mice, SCID; Microcirculation; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2016 |
Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbonic Anhydrase IX; Carbonic Anhydrases; Cyclophosphamide; Doxorubicin; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib | 2016 |
Codelivery of a miR-124 Mimic and Obatoclax by Cholesterol-Penetratin Micelles Simultaneously Induces Apoptosis and Inhibits Autophagic Flux in Breast Cancer in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Breast Neoplasms; Carrier Proteins; Cell Proliferation; Cell-Penetrating Peptides; Cholesterol; Female; Humans; Indoles; MCF-7 Cells; Mice; Mice, Nude; Micelles; MicroRNAs; Pyrroles; Real-Time Polymerase Chain Reaction; Wound Healing | 2016 |
Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Indoles; Middle Aged; Neoplasm Recurrence, Local; Pyrroles; Salvage Therapy; Sunitinib; Treatment Outcome; Ulcer | 2016 |
Fludioxonil induced the cancer growth and metastasis via altering epithelial-mesenchymal transition via an estrogen receptor-dependent pathway in cellular and xenografted breast cancer models.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cadherins; Cathepsin D; Cell Movement; Cell Proliferation; Cell Shape; Cyclin D1; Dioxoles; Epithelial-Mesenchymal Transition; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Pyrroles; Receptors, Estrogen; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Discriminant Analysis; Female; Gas Chromatography-Mass Spectrometry; Humans; Least-Squares Analysis; MCF-7 Cells; Metabolic Networks and Pathways; Metabolome; Metabolomics; Principal Component Analysis; Pyrroles | 2016 |
Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromones; Drug Synergism; Enzyme Inhibitors; Heterocyclic Compounds, 3-Ring; Humans; Morpholines; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles | 2016 |
FoxO3a is Essential for the Antiproliferative and Apoptogenic Effects of Sunitinib in MDA-MB231 Cell Line.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Forkhead Box Protein O3; Gene Silencing; Humans; Indoles; Oxidative Stress; Pyrroles; Sunitinib | 2016 |
A novel method for sensitive microRNA detection: Electropolymerization based doping.
Topics: Biosensing Techniques; Breast Neoplasms; Dielectric Spectroscopy; Electrochemical Techniques; Electrodes; Female; Graphite; Humans; Limit of Detection; MCF-7 Cells; MicroRNAs; Nucleic Acid Hybridization; Polymerization; Polymers; Pyrroles; RNA Probes | 2017 |
Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme.
Topics: Amination; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Male; Molecular Docking Simulation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2017 |
Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.
Topics: Angiogenesis Inhibitors; Animals; Aquaporin 1; Breast Neoplasms; Carrier Proteins; Cell Movement; Cytokines; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Indoles; Luminescent Measurements; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib | 2017 |
Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.
Topics: Angiogenesis Inhibitors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Oxindoles; Propionates; Pyrroles; Quality of Life; Taxoids | 2017 |
Label-free target DNA recognition using oligonucleotide-functionalized polypyrrole nanotubes.
Topics: Breast Neoplasms; DNA, Neoplasm; Female; Genes, Neoplasm; Humans; Microscopy, Confocal; Microscopy, Scanning Probe; Nanotubes; Oligonucleotides; Polymers; Pyrroles | 2008 |
Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Atorvastatin; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potential, Mitochondrial; Necrosis; Oxidative Stress; Pyrroles; Reactive Oxygen Species; Simvastatin | 2008 |
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Humans; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; Trastuzumab | 2008 |
Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspases; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Indoles; Mice; Mice, SCID; Microcirculation; Pain; Pyrroles; Radiation-Sensitizing Agents; Sunitinib; Tumor Burden | 2008 |
Major response to sunitinib (Sutene) in metastatic malignant phyllodes tumor of breast.
Topics: Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phyllodes Tumor; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Specific activity of class II histone deacetylases in human breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Estrogen Receptor alpha; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylases; Humans; Hydroxamic Acids; Pyrroles; Repressor Proteins; Signal Transduction | 2008 |
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib | 2009 |
Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; NF-kappa B; Pyrroles; Pyrrolidines; Thiocarbamates; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2009 |
Screening of a PKC zeta-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis.
Topics: Actins; Benzylamines; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Chemotaxis; Cofilin 1; Epidermal Growth Factor; Female; Humans; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles | 2010 |
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; Humans; Insulin Receptor Substrate Proteins; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1 | 2009 |
In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Molecular Structure; Pyrroles; Quinolones; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2009 |
Synthesis and antiproliferative activity of 2,4-disubstituted 6-aryl-7H-pyrrolo[3,2-d]pyrimidin-7-one 5-oxides.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Oxides; Pyrimidines; Pyrroles | 2009 |
Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Goserelin; Hematoma, Subdural, Intracranial; Humans; Indoles; Letrozole; Leukopenia; Nitriles; Pyrroles; Skull; Sunitinib; Triazoles | 2009 |
Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells.
Topics: 1-Methyl-3-isobutylxanthine; 8-Bromo Cyclic Adenosine Monophosphate; Apoptosis; Breast Neoplasms; Carbazoles; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclin-Dependent Kinase Inhibitor p27; Female; G1 Phase; Humans; Leptin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction | 2009 |
Sunitinib in breast cancer: friend or foe.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Indoles; Pyrroles; Sunitinib; Taxoids | 2009 |
Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Docetaxel; Female; Humans; Indoles; Liver Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Pyrroles; Sunitinib; Taxoids; Tomography, X-Ray Computed | 2009 |
Recombinant peptides as biomarkers for tumor response to molecular targeted therapy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Peptide Library; Peptides; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pyrroles; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Xenograft Model Antitumor Assays | 2010 |
Protein kinase A and regulation of neonatal Nav1.5 expression in human breast cancer cells: activity-dependent positive feedback and cellular migration.
Topics: Animals; Breast Neoplasms; Carbazoles; Cell Line, Tumor; Cell Movement; Colforsin; Cyclic AMP-Dependent Protein Kinases; Feedback, Physiological; Gene Expression Regulation, Neoplastic; Humans; Infant, Newborn; Muscle Proteins; NAV1.5 Voltage-Gated Sodium Channel; Neoplasm Invasiveness; Phosphorylation; Pyrroles; Rats; Sodium Channels; Stromal Cells; Tetrodotoxin; Up-Regulation | 2010 |
Role of glutathione transferases in the mechanism of brostallicin activation.
Topics: Antineoplastic Agents; Breast Neoplasms; Catalysis; Cell Line, Tumor; DNA; Female; Glutathione S-Transferase pi; Glutathione Transferase; Guanidines; Humans; Kinetics; Pyrroles | 2010 |
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapy.
Topics: Biomarkers; Breast Neoplasms; Cells, Cultured; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Male; Monitoring, Physiologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; T-Lymphocytes; Transcription, Genetic | 2010 |
Breast cancer: complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Diarrhea; Female; Heart Function Tests; Humans; Hypothyroidism; Indoles; Lymphatic Metastasis; Middle Aged; Paclitaxel; Pyrroles; Remission Induction; Sunitinib; Trastuzumab | 2010 |
Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-a]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II.
Topics: Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Design; Esters; Female; Humans; Leukemia; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinoxalines | 2010 |
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Topics: Alanine; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Random Allocation; Receptor, Fibroblast Growth Factor, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Transplantation, Heterologous; Triazines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors.
Topics: Animals; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Male; Mice; Molecular Imaging; Platelet Endothelial Cell Adhesion Molecule-1; Protein Engineering; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Technetium; Time Factors; Tomography, Emission-Computed, Single-Photon; Vascular Endothelial Growth Factor A | 2010 |
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrazoles; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2010 |
Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Bone Neoplasms; Breast Neoplasms; Contrast Media; Diphosphonates; Humans; Imidazoles; Indoles; Longitudinal Studies; Magnetic Resonance Imaging; Pyrroles; Random Allocation; Rats; Rats, Nude; Sunitinib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A down-regulation in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Carbazoles; Cell Line, Tumor; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; Cyclic AMP-Dependent Protein Kinases; Down-Regulation; Enzyme Activators; Female; Humans; Leptin; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Recombinant Proteins; Signal Transduction; STAT3 Transcription Factor; Time Factors; Up-Regulation | 2010 |
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; RNA, Small Interfering; Transfection; Trastuzumab | 2011 |
SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sunitinib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Design, synthesis and qualitative structure-activity evaluations of novel hexahydropyrano[3,2-c][1,2]diazepin-3(4H)-one and tetrahydropyrano[3,2-b]pyrrol-2(1H)-one derivatives as anticancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Neoplasms; Pyrans; Pyrroles; Structure-Activity Relationship | 2010 |
Chiral 6-hydroxymethyl-1H,3H-pyrrolo[1,2-c]thiazoles: novel antitumor DNA monoalkylating agents.
Topics: Adenocarcinoma; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; DNA; Drug Screening Assays, Antitumor; Female; Humans; Melanoma; Pyrroles; Thiazoles | 2010 |
Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA.
Topics: Animals; beta-Galactosidase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Duocarmycins; Female; Humans; Indoles; Mice; Mice, Nude; Microscopy, Fluorescence; Oncolytic Virotherapy; Prodrugs; Pyrroles; Vaccinia virus; Xenograft Model Antitumor Assays | 2011 |
Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Female; Flavonoids; Fluorescent Antibody Technique; Gene Knockout Techniques; Humans; Indoles; Lapatinib; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Piperidines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrroles; Quinazolines; Roscovitine | 2010 |
The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress.
Topics: Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Corticotropin-Releasing Hormone; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred BALB C; Pyrimidines; Pyrroles; Radioimmunoassay; Reverse Transcriptase Polymerase Chain Reaction; Stress, Physiological | 2010 |
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Edema; Female; Male; Mice; Pyrroles | 2011 |
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Indoles; Lapatinib; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sunitinib | 2011 |
Atorvastatin activates heme oxygenase-1 at the stress response elements.
Topics: Apoptosis; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Female; Heme Oxygenase-1; Heptanoic Acids; Humans; Male; Oxidative Stress; Polyisoprenyl Phosphates; Promoter Regions, Genetic; Prostatic Neoplasms; Pyrroles; Signal Transduction; Transcriptional Activation; Up-Regulation | 2012 |
Synthesis and biological evaluation of estradiol linked pyrrolo[2,1-c][1,4]benzodiazepine (PBD) conjugates as potential anticancer agents.
Topics: Antineoplastic Agents; Benzodiazepines; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Estradiol; Estrogens; Female; Humans; Pyrroles; Structure-Activity Relationship; Tubulin | 2011 |
Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Indoles; Pyrroles; Quality Control; Reference Standards; Sunitinib | 2011 |
Design, synthesis and biological evaluation of novel 4-thiazolidinones containing indolin-2-one moiety as potential antitumor agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Female; Fibroblasts; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Lung Neoplasms; Pyrroles; Sunitinib; Thiazolidines | 2011 |
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Atorvastatin; Benzylamines; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heptanoic Acids; Humans; Lovastatin; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Thiophenes | 2011 |
Licofelone-nitric oxide donors as anticancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Nitric Oxide Donors; Pyrroles | 2011 |
New perspectives: role of Sunitinib in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Indoles; Pyrroles; Sunitinib | 2011 |
Targeted systemic radiotherapy with scVEGF/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Bevacizumab; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endothelial Cells; Female; Humans; Indoles; Lutetium; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Radioisotopes; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Development of 2,3,5-triaryl-1H-pyrroles as estrogen receptor α selective ligands.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; Drug Stability; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Humans; Models, Molecular; Phenols; Pyrazoles; Pyrroles; Structure-Activity Relationship | 2011 |
Trastuzumab-related palmar plantar erythrodysaesthesia.
Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agents; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Foot Dermatoses; Hand Dermatoses; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Trastuzumab | 2012 |
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo.
Topics: Amino Acids; Animals; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, SCID; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiation-Sensitizing Agents; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Xanthenes; Xenograft Model Antitumor Assays | 2011 |
The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer.
Topics: Acetylation; Benzamides; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Dioxoles; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Genetic Loci; Histones; Humans; Intercellular Junctions; Mammary Glands, Human; Phenotype; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; RNA, Messenger; Signal Transduction; Snail Family Transcription Factors; Substrate Specificity; Transcription Factors; Transcription, Genetic; Transforming Growth Factor beta | 2011 |
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured | 2012 |
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sunitinib | 2012 |
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.
Topics: Angiogenesis Inhibitors; Animals; beta Catenin; Breast Neoplasms; Cell Count; Cell Hypoxia; Cell Line, Tumor; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Neoplastic Stem Cells; Pyrroles; Signal Transduction; Sunitinib | 2012 |
New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Models, Molecular; Pyridines; Pyrroles; Structure-Activity Relationship | 2012 |
Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model.
Topics: Animals; Beclomethasone; Breast Neoplasms; Cell Movement; Cell Transformation, Neoplastic; Disease Models, Animal; Endothelial Cells; Humans; Indoles; Mice; Myeloid Cells; Neoplasm Metastasis; Neutrophils; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Xenograft Model Antitumor Assays; Zebrafish | 2012 |
Identification of a selective small molecule inhibitor of breast cancer stem cells.
Topics: Breast Neoplasms; Female; Humans; Hydrazones; Neoplastic Stem Cells; Pyrroles | 2012 |
HIF1A induces expression of the WASF3 metastasis-associated gene under hypoxic conditions.
Topics: Breast Neoplasms; Cell Hypoxia; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Neoplasm Metastasis; Pyrroles; Transcription, Genetic; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Wiskott-Aldrich Syndrome Protein Family | 2012 |
Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Immunosuppressive Agents; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases; Sirolimus; Tumor Cells, Cultured | 2013 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome | 2012 |
Phenotypic high-throughput screening elucidates target pathway in breast cancer stem cell-like cells.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Hydrazones; Inhibitory Concentration 50; Neoplastic Stem Cells; NF-kappa B; Pyrroles; Small Molecule Libraries | 2012 |
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Breast Neoplasms; Cell Line, Tumor; eIF-2 Kinase; Endoplasmic Reticulum Stress; Female; HSP70 Heat-Shock Proteins; Humans; Indoles; Lapatinib; Membrane Proteins; Mice; Mice, Nude; Mitochondria; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; p38 Mitogen-Activated Protein Kinases; Pyrroles; Quinazolines; Reactive Oxygen Species | 2012 |
Influence of chlorine or fluorine substitution on the estrogenic properties of 1-alkyl-2,3,5-tris(4-hydroxyphenyl)-1H-pyrroles.
Topics: Blotting, Western; Breast Neoplasms; Cell Proliferation; Chlorine; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fluorine; Humans; Luciferases; Models, Molecular; Osteosarcoma; Phenols; Protein Binding; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Female; Humans; Middle Aged; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; Trastuzumab; Treatment Outcome | 2012 |
Synthesis and docking studies of novel antitumor benzimidazoles.
Topics: Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Herpesvirus 4, Human; Humans; Lung Neoplasms; MCF-7 Cells; Models, Molecular; Pyrroles; Structure-Activity Relationship; Tetracyclines; Virus Activation | 2012 |
Lead optimization of a dihydropyrrolopyrimidine inhibitor against phosphoinositide 3-kinase (PI3K) to improve the phenol glucuronic acid conjugation.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Crystallography, X-Ray; Enzyme Activation; Female; Glucuronic Acid; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Mice; Molecular Structure; Phenols; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2013 |
Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP1A1; Dactinomycin; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Female; Gene Expression Regulation, Enzymologic; Humans; Indoles; Ligands; MCF-7 Cells; Protein-Tyrosine Kinases; Pyrroles; Receptors, Aryl Hydrocarbon; Resveratrol; RNA, Messenger; Stilbenes; Sunitinib; Transcriptional Activation | 2013 |
Chiral 6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles with anti-breast cancer properties.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Pyrroles; Structure-Activity Relationship; Thiazoles | 2013 |
Preclinical evaluation of sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases.
Topics: Acid Phosphatase; Angiogenesis Inhibitors; Animals; Antigens, CD34; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Indoles; Isoenzymes; Mice; Mice, Nude; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tartrate-Resistant Acid Phosphatase; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
GX15-070 (obatoclax) induces apoptosis and inhibits cathepsin D- and L-mediated autophagosomal lysis in antiestrogen-resistant breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Breast Neoplasms; Cathepsin D; Cathepsin L; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Indoles; Lysosomes; Membrane Proteins; Mice; Microtubule-Associated Proteins; Phagosomes; Pyrroles; Sequestosome-1 Protein; Transplantation, Heterologous | 2013 |
Cell-free and cellular activities of a DNA sequence selective hairpin polyamide-CBI conjugate.
Topics: Alkylating Agents; Base Sequence; Breast Neoplasms; Cell Cycle; Cell Division; DNA; DNA Damage; DNA, Viral; Female; Humans; Indoles; Nucleic Acid Conformation; Nylons; Oligodeoxyribonucleotides; Pyrroles; Simian virus 40; Tumor Cells, Cultured | 2002 |
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Humans; Indoles; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Transplantation; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib; Time Factors | 2003 |
Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.
Topics: Aerobiosis; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Humans; Indoles; NADPH-Ferrihemoprotein Reductase; Pyrroles; Transfection | 2003 |
SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Osteoclasts; Osteolysis; Phosphorylation; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Macrophage Colony-Stimulating Factor; Sunitinib; Tumor Cells, Cultured | 2003 |
Inhibitory effect of statins on the proliferation of human breast cancer cells.
Topics: Anticholesteremic Agents; Apoptosis; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Antagonism; Estradiol; Estrogens; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Neoplasms, Hormone-Dependent; Pyrroles | 2004 |
Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget.
Topics: Alkaline Phosphatase; Amino Acid Substitution; Benzoxazines; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Humans; Ligands; Mutagenesis, Site-Directed; Promegestone; Pyrroles; Receptors, Progesterone; Recombinant Proteins; X-Ray Diffraction | 2005 |
SAR studies of 6-aryl-1,3-dihydrobenzimidazol-2-ones as progesterone receptor antagonists.
Topics: Benzimidazoles; Benzoxazines; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Female; Hormone Antagonists; Humans; Indoles; Pyrroles; Receptors, Progesterone; Structure-Activity Relationship | 2005 |
The pyrrolo-1,5-benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Survival; Female; Humans; Mice; Mice, Inbred BALB C; Oxazepines; Pyrroles; Receptor, ErbB-2; Receptors, Estrogen; Tumor Cells, Cultured | 2005 |
Cytotoxicity of novel derivatives of the spin trap EMPO.
Topics: Breast Neoplasms; Cell Death; Colonic Neoplasms; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Fibroblasts; Free Radicals; Humans; Lung Neoplasms; Pyrroles; Spin Labels; Spin Trapping; Structure-Activity Relationship; Tumor Cells, Cultured | 2006 |
Assessment of anti-metastatic drug efficacy via localization and quantification of ex vivo murine bone tumor load using high-throughput MRI T1 parametric analysis.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Prognosis; Pyrroles; Sunitinib; Treatment Outcome | 2006 |
Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Dose-Response Relationship, Drug; Female; Humans; Incidence; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase C; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrimidines; Pyrroles; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays | 2006 |
Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.
Topics: Autocrine Communication; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Corticotropin-Releasing Hormone; Dose-Response Relationship, Drug; Estradiol; Female; Hormones; Humans; Paracrine Communication; Pyrimidines; Pyrroles; Receptors, Corticotropin-Releasing Hormone | 2007 |
Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Cell Line; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Isoenzymes; Luciferases; Mesylates; Mutation; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-fos; Pyrroles; Recombinant Fusion Proteins; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transfection | 2006 |
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Lapatinib; Nitriles; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2007 |
Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison.
Topics: Aging; Antineoplastic Agents; Autophagy; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromosome Aberrations; Drug Resistance, Neoplasm; Humans; Microtubules; Molecular Structure; Polyploidy; Pyrroles; Time Factors | 2007 |
Off-label uses of sorafenib and sunitinib.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Digestive System Neoplasms; Drug Approval; Female; Gastrointestinal Stromal Tumors; Head and Neck Neoplasms; Humans; Indoles; Male; Melanoma; Neoplasms, Squamous Cell; Product Labeling; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Activity of bis-carbamoyloxymethyl derivatives of pyrroles and pyrrolizines against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Small Cell; Cell Line; Colonic Neoplasms; Drug Evaluation, Preclinical; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Pyrroles; Pyrrolidines; Transplantation, Heterologous | 1982 |
Synthesis and murine antineoplastic activity of bis[(carbamoyloxy)methyl] derivatives of pyrrolo[2,1-a]isoquinoline.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carbamates; Chemical Phenomena; Chemistry; Isoquinolines; Leukemia P388; Magnetic Resonance Spectroscopy; Mice; Neoplasms, Experimental; Pyrroles; Spectrophotometry, Infrared; Structure-Activity Relationship; Transplantation, Heterologous | 1984 |
Identification of a 170 kDa membrane kinase with increased activity in KB-V1 multidrug resistant cells.
Topics: Alkaloids; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Calcium; Carbazoles; Carrier Proteins; Clone Cells; Cyclic AMP; Drug Resistance; Electrophoresis, Polyacrylamide Gel; Humans; Indole Alkaloids; Indoles; KB Cells; Melanoma, Experimental; Membrane Glycoproteins; Mice; Neoplasm Proteins; Phosphatidylserines; Phosphorylation; Phosphothreonine; Phosphotyrosine; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyrroles; Staurosporine; Transfection; Tumor Cells, Cultured; Tyrosine | 1993 |
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.
Topics: Amino Acid Sequence; Animals; Antibiotics, Antineoplastic; Binding, Competitive; Breast Neoplasms; Doxorubicin; Female; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Molecular Sequence Data; Pituitary Gland; Pyrroles; Rats; Receptors, LHRH; Tumor Cells, Cultured | 1996 |
Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Division; Doxorubicin; Female; Growth Hormone; Humans; Immunotoxins; Luteinizing Hormone; Mice; Mice, Nude; Pyrroles; Receptors, Somatostatin; Transplantation, Heterologous | 1999 |
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrate; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Middle Aged; Pyrroles; Simvastatin; Tamoxifen; Treatment Outcome | 1999 |
Cycloprodigiosin hydrochloride, a H+/Cl- symporter, induces apoptosis in human breast cancer cell lines.
Topics: Antiporters; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle; Cell Division; Humans; Hydrogen-Ion Concentration; Immunosuppressive Agents; Indoles; Membrane Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proton-Translocating ATPases; Pyrroles; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Vacuolar Proton-Translocating ATPases | 2000 |
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; DNA Primers; Doxorubicin; Drug Delivery Systems; Female; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Radioligand Assay; Receptors, LHRH; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Specific Pathogen-Free Organisms; Tumor Cells, Cultured | 2000 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Topics: Adenylyl Cyclases; Breast Neoplasms; Carbazoles; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; ErbB Receptors; Estradiol; Estrogen Antagonists; Estrogens; Fulvestrant; Humans; Indoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-raf; Pyrroles; Receptors, Cell Surface; Receptors, Estrogen; Receptors, G-Protein-Coupled; Tamoxifen; Tumor Cells, Cultured | 2002 |
Caspase-3 is not essential for DNA fragmentation in MCF-7 cells during apoptosis induced by the pyrrolo-1,5-benzoxazepine, PBOX-6.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Caspase 3; Caspase 7; Caspases; DNA Fragmentation; Enzyme Activation; Female; Flow Cytometry; Humans; In Situ Nick-End Labeling; Oxazepines; Pyrroles; Tumor Cells, Cultured | 2002 |
Synergistic effects induced by cycloprodigiosin hydrochloride and epirubicin on human breast cancer cells.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Female; Flow Cytometry; Humans; In Situ Nick-End Labeling; Indoles; Injections, Intraperitoneal; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Microscopy, Confocal; Phosphorus Radioisotopes; Pyrroles; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Betacellulin; Breast Neoplasms; Cell Division; Drug Interactions; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; G1 Phase; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Ligands; Neuregulin-1; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Substrate Specificity; Tumor Cells, Cultured | 2002 |